It is all about MC and EV. NYR now trading at above $20m, EV $ 15m for just 1 pre-clinical asset. If that 15m is fairly valued then CHM's current EV of just $6m should be several hundreds of millions considering the stage of development of CHM's assets and world's best clinical data. Treating both, brain injuries and brain cancer, is important but I don't think that GBM is worth nothing to what NYR got.
But NYR shows when the board let's the market have its say and let it run before a CR then a premium will be achieved. That is what makes the difference between Discount-Hopper and NYR decision makers. There is plenty of money out there, Hopper either insanely refused to take it or deliberately sank the 3 comps to provide a very low entry for his mates. Both would be legal but highly unethical.
GLTA
- Forums
- ASX - By Stock
- CHM
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-9
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.7¢ | $18.43K | 1.042M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 2833886 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 569796 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 2833886 | 0.016 |
19 | 2586784 | 0.015 |
3 | 708475 | 0.014 |
2 | 222223 | 0.013 |
2 | 83412 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 569796 | 3 |
0.019 | 1360467 | 5 |
0.020 | 1473093 | 6 |
0.021 | 871092 | 3 |
0.022 | 600000 | 2 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |